HK1199269A1 - Anti-asic1 antibodies and uses thereof -asic1 - Google Patents

Anti-asic1 antibodies and uses thereof -asic1

Info

Publication number: HK1199269A1
Authority: HK; Hong Kong
Prior art keywords: asic1; antibodies; asic1 antibodies
Prior art date: 2012-01-31

Application number

HK14112815.2A

Other languages

English (en)

Chinese (zh)

Inventor

Lynn Macdonald

Min Gao

Marc R Morra

Nicole M Alessandri-Haber

Michael L Lacroix-Fralish

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-31

Filing date

2014-12-23

Publication date

2015-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199269(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-23 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2015-06-26 Publication of HK1199269A1 publication Critical patent/HK1199269A1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HK14112815.2A 2012-01-31 2014-12-23 Anti-asic1 antibodies and uses thereof -asic1 HK1199269A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261592837P	2012-01-31	2012-01-31
US201261644038P	2012-05-08	2012-05-08
US201261692925P	2012-08-24	2012-08-24
PCT/US2013/023784 WO2013116296A1 (en)	2012-01-31	2013-01-30	Anti-asic1 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
HK1199269A1 true HK1199269A1 (en)	2015-06-26

Family

ID=47666522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK14112815.2A HK1199269A1 (en)	2012-01-31	2014-12-23	Anti-asic1 antibodies and uses thereof -asic1

Country Status (33)

Country	Link
US (3)	US9150648B2 (pt)
EP (2)	EP3453723B1 (pt)
JP (1)	JP6302844B2 (pt)
KR (1)	KR102111941B1 (pt)
CN (1)	CN104093738B (pt)
AR (1)	AR089852A1 (pt)
AU (1)	AU2013215254B2 (pt)
CA (1)	CA2862332C (pt)
CL (1)	CL2014002019A1 (pt)
CO (1)	CO7020877A2 (pt)
CY (2)	CY1121368T1 (pt)
DK (2)	DK2809681T3 (pt)
EA (1)	EA028647B1 (pt)
ES (2)	ES2707599T3 (pt)
HK (1)	HK1199269A1 (pt)
HR (2)	HRP20211541T1 (pt)
HU (2)	HUE056335T2 (pt)
IL (2)	IL233410A0 (pt)
IN (1)	IN2014CN04645A (pt)
JO (1)	JO3547B1 (pt)
LT (2)	LT3453723T (pt)
MX (1)	MX358518B (pt)
MY (1)	MY168748A (pt)
NZ (1)	NZ626242A (pt)
PH (1)	PH12014501613A1 (pt)
PL (2)	PL2809681T3 (pt)
PT (2)	PT2809681T (pt)
RS (2)	RS58439B1 (pt)
SG (1)	SG11201403222UA (pt)
SI (2)	SI2809681T1 (pt)
TW (1)	TWI591073B (pt)
UY (1)	UY34603A (pt)
WO (1)	WO2013116296A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2707599T3 (es)	2012-01-31	2019-04-04	Regeneron Pharma	Anticuerpos anti-asic1 y usos de los mismos
CA2945498A1 (en)	2014-04-15	2015-10-22	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind wisp1
KR20230053002A (ko)	2014-05-16	2023-04-20	아블린쓰 엔.브이.	개선된 면역글로불린 가변 도메인
CN105233286B (zh) *	2015-09-10	2018-10-30	上海交通大学医学院	含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) *	2016-02-26	2019-08-06	上海科技大学	一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) *	2016-11-01	2018-05-11	Berg Llc	Filamin b binding proteins and uses thereof
MX2020007888A (es) *	2018-01-26	2020-09-07	Regeneron Pharma	Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
KR20220016891A (ko) *	2019-06-04	2022-02-10	상하이테크 유니버시티	친화성-성숙된 항-ASIC1a 항체
BR112022000216A2 (pt) *	2019-07-11	2022-05-17	Memorial Sloan Kettering Cancer Center	Anticorpos direcionados a dll3 e usos dos mesmos
US20230287107A1 (en) *	2019-07-23	2023-09-14	Shanghaitech University	Asic1 channel antagonist antibody
AU2020346886A1 (en) *	2019-09-13	2022-04-14	Memorial Hospital For Cancer And Allied Diseases	Anti-CD371 antibodies and uses thereof
IL310700A (en) *	2021-08-09	2024-04-01	Merck Patent Gmbh	Proteins that uncouple cell-mediated tumor cytotoxicity from proinflammatory cytokine release
AU2022337142A1 (en) *	2021-09-02	2024-03-07	Memorial Hospital For Cancer And Allied Diseases	Anti-dll3 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2759373B1 (fr)	1997-02-11	2001-05-04	Centre Nat Rech Scient	Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
DE69836591T2 (de)	1997-10-29	2007-09-20	Mcgill University, Montreal	Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen
US6287859B1 (en)	1998-08-05	2001-09-11	Centre National De La Recherche	Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en)	2000-04-20	2001-10-20	Philippe Seguela	A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en)	2000-04-25	2003-10-21	University Of Iowa Research Foundation	Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en)	2001-05-10	2006-11-07	Centre National De La Recherche Scientifique - Cnrs	Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) *	2001-07-18	2003-01-18	Philippe Seguela	Novel human proton gated ion channel
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20070197583A1 (en)	2002-03-29	2007-08-23	Welsh Michael J	Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
MXPA04009418A (es) *	2002-03-29	2005-06-08	Schering Corp	Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
US20030186860A1 (en)	2002-03-29	2003-10-02	Welsh Michael J.	Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
EP1667735A2 (en) *	2003-09-11	2006-06-14	The Uab Research Foundation	Inhibition of inward sodium currents in cancer
WO2005074923A1 (en)	2004-02-03	2005-08-18	Agt Biosciences Limited	Methods and compositions
EP1734962A4 (en)	2004-03-30	2010-07-14	Painceptor Pharma Corp	COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
US7192500B2 (en)	2004-04-30	2007-03-20	Kimberly-Clark Worldwide, Inc.	Process for making a garment including an absorbent assembly
US8030442B2 (en)	2004-09-16	2011-10-04	Morehouse School Of Medicine	Treatment of injury to the brain by inhibition of acid sensing ion channels
RU2394839C2 (ru) *	2004-12-21	2010-07-20	Астразенека Аб	Антитела против ангиопоэтина-2 и их применение
KR101193797B1 (ko) *	2005-04-26	2012-10-23	화이자 인코포레이티드	Ｐ-카드헤린 항체
ES2398076T3 (es)	2006-06-02	2013-03-13	Regeneron Pharmaceuticals, Inc.	Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JP5382692B2 (ja) *	2006-07-10	2014-01-08	学校法人藤田学園	抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
EP2043650A2 (en) *	2006-07-14	2009-04-08	Medical Research Council	Treatment for demyelinating disease
NO347649B1 (no) *	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en)	2007-01-30	2009-10-06	Academia Sinica	Treatment of insulin resistance
DE602008002913D1 (de)	2007-04-03	2010-11-18	Ilegusavnid Genetics Resource	Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
WO2008134659A2 (en) *	2007-04-27	2008-11-06	Zymogenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2288922B1 (en) *	2008-05-08	2016-08-17	University of Utah Research Foundation	Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en)	2008-05-21	2009-11-26	University Of Iowa Research Foundation	Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr)	2008-06-06	2012-12-28	Centre Nat Rech Scient	Effets analgesiques de la toxine peptidique apetx2
WO2010054010A1 (en) *	2008-11-07	2010-05-14	Fabrus Llc	Anti-dll4 antibodies and uses thereof
JO3672B1 (ar) *	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) *	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
GB0922434D0 (en) *	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
CN102234316B (zh) *	2010-05-07	2014-01-29	中国人民解放军军事医学科学院毒物药物研究所	具有增强酸感受离子通道1a电流作用的多肽及其用途
ES2707599T3 (es)	2012-01-31	2019-04-04	Regeneron Pharma	Anticuerpos anti-asic1 y usos de los mismos
US9371383B2 (en)	2012-01-31	2016-06-21	Regeneron Pharmaceuticals, Inc.	Anti-ASIC1 antibodies and uses thereof

2013
- 2013-01-30 ES ES13702876T patent/ES2707599T3/es active Active
- 2013-01-30 WO PCT/US2013/023784 patent/WO2013116296A1/en active Application Filing
- 2013-01-30 MX MX2014008541A patent/MX358518B/es active IP Right Grant
- 2013-01-30 PT PT13702876T patent/PT2809681T/pt unknown
- 2013-01-30 HU HUE18201823A patent/HUE056335T2/hu unknown
- 2013-01-30 RS RS20190287A patent/RS58439B1/sr unknown
- 2013-01-30 JP JP2014554950A patent/JP6302844B2/ja active Active
- 2013-01-30 EA EA201491452A patent/EA028647B1/ru not_active IP Right Cessation
- 2013-01-30 US US13/753,836 patent/US9150648B2/en active Active
- 2013-01-30 RS RS20211284A patent/RS62454B1/sr unknown
- 2013-01-30 DK DK13702876.7T patent/DK2809681T3/en active
- 2013-01-30 EP EP18201823.4A patent/EP3453723B1/en active Active
- 2013-01-30 NZ NZ626242A patent/NZ626242A/en unknown
- 2013-01-30 EP EP13702876.7A patent/EP2809681B1/en active Active
- 2013-01-30 SG SG11201403222UA patent/SG11201403222UA/en unknown
- 2013-01-30 DK DK18201823.4T patent/DK3453723T3/da active
- 2013-01-30 CA CA2862332A patent/CA2862332C/en active Active
- 2013-01-30 TW TW102103458A patent/TWI591073B/zh active
- 2013-01-30 KR KR1020147020682A patent/KR102111941B1/ko active IP Right Grant
- 2013-01-30 JO JOP/2013/0036A patent/JO3547B1/ar active
- 2013-01-30 LT LTEP18201823.4T patent/LT3453723T/lt unknown
- 2013-01-30 CN CN201380007553.3A patent/CN104093738B/zh active Active
- 2013-01-30 IN IN4645CHN2014 patent/IN2014CN04645A/en unknown
- 2013-01-30 SI SI201331343T patent/SI2809681T1/sl unknown
- 2013-01-30 PT PT182018234T patent/PT3453723T/pt unknown
- 2013-01-30 PL PL13702876T patent/PL2809681T3/pl unknown
- 2013-01-30 AU AU2013215254A patent/AU2013215254B2/en active Active
- 2013-01-30 PL PL18201823T patent/PL3453723T3/pl unknown
- 2013-01-30 HU HUE13702876A patent/HUE042531T2/hu unknown
- 2013-01-30 AR ARP130100280 patent/AR089852A1/es active IP Right Grant
- 2013-01-30 ES ES18201823T patent/ES2886123T3/es active Active
- 2013-01-30 SI SI201331923T patent/SI3453723T1/sl unknown
- 2013-01-30 MY MYPI2014001721A patent/MY168748A/en unknown
- 2013-01-30 LT LTEP13702876.7T patent/LT2809681T/lt unknown
- 2013-01-30 HR HRP20211541TT patent/HRP20211541T1/hr unknown
- 2013-01-31 UY UY34603A patent/UY34603A/es not_active Application Discontinuation
2014
- 2014-06-26 IL IL233410A patent/IL233410A0/en unknown
- 2014-07-11 PH PH12014501613A patent/PH12014501613A1/en unknown
- 2014-07-25 CO CO14162499A patent/CO7020877A2/es unknown
- 2014-07-30 CL CL2014002019A patent/CL2014002019A1/es unknown
- 2014-12-23 HK HK14112815.2A patent/HK1199269A1/xx unknown
2015
- 2015-09-09 US US14/848,452 patent/US20160002332A1/en not_active Abandoned
2017
- 2017-09-11 IL IL254416A patent/IL254416B/en active IP Right Grant
- 2017-09-28 US US15/719,220 patent/US10513557B2/en active Active
2019
- 2019-02-22 HR HRP20190358TT patent/HRP20190358T1/hr unknown
- 2019-02-27 CY CY20191100246T patent/CY1121368T1/el unknown
2021
- 2021-11-09 CY CY20211100968T patent/CY1124778T1/el unknown

Also Published As

Publication number	Publication date
LT3453723T (lt)	2021-09-10
PT3453723T (pt)	2021-09-07
US20130195878A1 (en)	2013-08-01
CN104093738A (zh)	2014-10-08
HRP20211541T1 (hr)	2021-12-24
KR20140125363A (ko)	2014-10-28
US9150648B2 (en)	2015-10-06
AU2013215254B2 (en)	2017-08-31
BR112014018651A2 (pt)	2017-07-04
IL254416A0 (en)	2017-11-30
HRP20190358T1 (hr)	2019-04-05
CA2862332C (en)	2021-05-18
WO2013116296A1 (en)	2013-08-08
JP2015508063A (ja)	2015-03-16
DK3453723T3 (da)	2021-09-13
CA2862332A1 (en)	2013-08-08
EP2809681B1 (en)	2018-12-05
EP3453723A2 (en)	2019-03-13
AR089852A1 (es)	2014-09-24
CL2014002019A1 (es)	2015-01-16
NZ626242A (en)	2017-02-24
LT2809681T (lt)	2019-02-11
EA201491452A1 (ru)	2014-11-28
US20160002332A1 (en)	2016-01-07
IL233410A0 (en)	2014-08-31
CY1124778T1 (el)	2022-11-25
DK2809681T3 (en)	2019-03-11
EP3453723A3 (en)	2019-04-10
PL3453723T3 (pl)	2022-01-03
TWI591073B (zh)	2017-07-11
JO3547B1 (ar)	2020-07-05
IN2014CN04645A (pt)	2015-09-18
PH12014501613B1 (en)	2014-10-13
ES2886123T3 (es)	2021-12-16
UY34603A (es)	2013-07-31
US10513557B2 (en)	2019-12-24
RS58439B1 (sr)	2019-04-30
PL2809681T3 (pl)	2019-05-31
MX358518B (es)	2018-08-24
IL254416B (en)	2018-03-29
SI3453723T1 (sl)	2021-11-30
CY1121368T1 (el)	2020-05-29
MX2014008541A (es)	2014-10-24
JP6302844B2 (ja)	2018-03-28
SI2809681T1 (sl)	2019-04-30
US20180222976A1 (en)	2018-08-09
SG11201403222UA (en)	2014-07-30
EP2809681A1 (en)	2014-12-10
CO7020877A2 (es)	2014-08-11
EA028647B1 (ru)	2017-12-29
PT2809681T (pt)	2019-02-18
CN104093738B (zh)	2018-05-18
RS62454B1 (sr)	2021-11-30
PH12014501613A1 (en)	2014-10-13
HUE056335T2 (hu)	2022-02-28
HUE042531T2 (hu)	2019-07-29
ES2707599T3 (es)	2019-04-04
MY168748A (en)	2018-11-30
KR102111941B1 (ko)	2020-05-18
TW201335182A (zh)	2013-09-01
EP3453723B1 (en)	2021-08-11
AU2013215254A1 (en)	2014-07-03

Publication	Publication Date	Title
IL266893B (en)	2020-02-27	Meditops and Meditop binding antibodies and their use
HK1207092A1 (en)	2016-01-22	Anti-hla-b27 antibodies and uses thereof -hla-b27
HRP20190358T1 (hr)	2019-04-05	Antitijela protiv asic1 i njihova primjena
IL238559B (en)	2018-10-31	Antibodies against ceacam5 and their use
ZA201407927B (en)	2015-11-25	Anti-egfr antibodies and uses thereof
HK1207654A1 (en)	2016-02-05	Modified antibody regions and uses thereof
EP2832856A4 (en)	2016-01-27	ANTI-LAMP5 ANTIBODIES AND USE THEREOF
HK1205523A1 (en)	2015-12-18	Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof ---1(big-et-1)
HK1199842A1 (en)	2015-07-24	Anti-siglec-15 antibodies and uses thereof -15
GB201208372D0 (en)	2012-06-27	Antibodies and uses thereof